PolyPid’s (PYPD) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of PolyPid (NASDAQ:PYPD) in a research report report published on Wednesday morning,Benzinga reports. The brokerage currently has a $13.00 target price on the stock. HC Wainwright also issued estimates for PolyPid’s Q1 2026 earnings at ($0.49) EPS, Q2 2026 earnings at ($0.47) EPS, Q3 2026 earnings at ($0.39) EPS, Q4 2026 earnings at ($0.37) EPS, FY2026 earnings at ($1.69) EPS, FY2027 earnings at ($0.68) EPS, FY2028 earnings at $0.21 EPS, FY2029 earnings at $1.90 EPS and FY2030 earnings at $4.02 EPS.

PYPD has been the topic of several other reports. Roth Mkm lowered their price objective on shares of PolyPid from $10.00 to $9.00 and set a “buy” rating on the stock in a research report on Thursday, November 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of PolyPid in a research note on Monday, December 29th. Wall Street Zen raised PolyPid from a “sell” rating to a “hold” rating in a report on Sunday, November 16th. Finally, Citigroup restated a “market outperform” rating on shares of PolyPid in a research report on Monday, December 1st. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, PolyPid currently has an average rating of “Moderate Buy” and an average price target of $12.25.

PolyPid Stock Down 3.5%

PYPD opened at $4.43 on Wednesday. PolyPid has a 52 week low of $2.30 and a 52 week high of $5.12. The business’s 50 day moving average is $4.37 and its two-hundred day moving average is $3.81. The firm has a market cap of $70.44 million, a price-to-earnings ratio of -1.96 and a beta of 1.52.

PolyPid (NASDAQ:PYPD) last announced its earnings results on Wednesday, February 11th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.07). Equities analysts expect that PolyPid will post -1.79 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. BNP Paribas Financial Markets grew its stake in PolyPid by 56.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock valued at $32,000 after acquiring an additional 3,500 shares during the last quarter. HighTower Advisors LLC purchased a new stake in shares of PolyPid in the fourth quarter valued at about $44,000. Jane Street Group LLC acquired a new stake in shares of PolyPid in the fourth quarter valued at approximately $66,000. Lumbard & Kellner LLC acquired a new stake in shares of PolyPid in the second quarter valued at approximately $135,000. Finally, AIGH Capital Management LLC increased its stake in shares of PolyPid by 27.0% during the 2nd quarter. AIGH Capital Management LLC now owns 1,194,108 shares of the company’s stock worth $4,215,000 after purchasing an additional 253,727 shares in the last quarter. Institutional investors and hedge funds own 26.47% of the company’s stock.

Key PolyPid News

Here are the key news stories impacting PolyPid this week:

• Positive Sentiment: HC Wainwright maintains a “Buy” rating and a $13 price target and models significant long‑term upside (FY2028 and FY2030 estimates were raised to positive territory), which supports a bullish narrative for PYPD’s eventual commercial prospects.
• Positive Sentiment: Management’s Q4 earnings call was described as upbeat and flagged a potentially material 2026 catalyst that investors may view as a near‑term growth trigger. PolyPid Earnings Call Flags Big 2026 Catalyst
• Neutral Sentiment: Full Q4 2025 earnings call transcript and highlight coverage are available for investors who want details on pipeline timing, trial milestones and cash guidance; these provide context but may not move the stock until the 2026 catalyst is clarified. Q4 2025 Earnings Call Highlights Q4 2025 Earnings Call Transcript
• Negative Sentiment: HC Wainwright materially lowered FY2026 EPS estimates (now forecasting a larger loss: -$1.69 vs prior -$1.46) and trimmed FY2029 slightly, signaling worse near‑term profitability than previously expected — a negative for short‑term sentiment.
• Negative Sentiment: PolyPid missed Q4 EPS expectations (reported -$0.41 vs consensus -$0.34), underscoring current cash‑burn/loss trends that weigh on the share price until clinical or commercial catalysts materialize. Earnings Call Transcript

PolyPid Company Profile

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.